Search
for
Sort by
Research 61–90 of 674
- Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment
- Effective counseling of patients with hair loss
- Scalp hair regrowth is associated with improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata: results from two randomized controlled trials
- Patient characteristics associated with all-cause healthcare costs of alopecia areata in the United States
- Androgenetic alopecia; An attempt to target microinflammation
- In Vivo Imaging Techniques for the Human Scalp: A Systematic Review of the Literature
- 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials
- 54022 Pooled Safety Assessments from the Multinational Phase 3 THRIVE-AA1 and THRIVE-AA2 Trials of Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata
- Concordance between clinician-reported and patient-reported outcomes of eyebrow and eyelash hair loss in patients with severe alopecia areata: Results from BRAVE-AA1 and BRAVE-AA2 studies
- 41701 Efficacy of the Oral JAK1/JAK2 Inhibitor CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata: Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 Phase 3 Trial
- COVID-19 vaccination related exacerbations of hair loss in patients with moderate-to-severe alopecia areata on systemic therapy
- Not just thinning: A case of alopecia universalis after mild COVID-19
- Association of resilience and perceived stress in patients with alopecia areata: A cross-sectional study
- A New Horizon in Facial Plastic Surgery: Skin Tissue-Engineering and Stem Cell Therapy—Reality or Dream?
- Improvement in Patient‐Reported Emotional Symptoms and Activity Limitations due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From ALLEGRO ‐2b/3
- Dermatological adverse reactions and therapeutic potential of semaglutide, liraglutide and tirzepatide: Analysis of UK pharmacovigilance data and literature review
- Components of Severity in Alopecia Areata
- Keloid Formation and Any Skin Complications in Patients Treated With Isotretinoin and Undergone Any Skin‐Related Procedures
- Blood Pressure Monitoring for Minoxidil Therapy in Alopecia Patients
- 41915 Improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata achieving scalp hair regrowth: results from two randomized controlled trials
- 44313 Self-Stigmatization and Alopecia Areata; Exploring the Role of Social Support, Helplessness, and Illness Acceptance
- Real-World Treatment Patterns among Patients with Alopecia Areata in the USA: A Retrospective Claims Analysis
- Expanding Wig Coverage under Medicare: Improving Access for Patients with Alopecia.
- Patient satisfaction and adverse effects following the use of topical hair fiber fillers
- 27604 Response to baricitinib in the treatment of patients with early and late onset alopecia areata in the phase 2 portion of BRAVE-AA1 randomized controlled trial
- Delphi Consensus Statement on Treatment of Severe Alopecia Areata in US Adults
- Upadacitinib for Severe Alopecia Areata in Adults and Adolescents
- Metabolic and Psychiatric Comorbidities in Dissecting Cellulitis of the Scalp: A Retrospective Cohort Study and Scoping Review
- Hair follicles as immune targets: unraveling cellular players, cytokine crosstalk, and precision pathways for future therapy of alopecia areata
- 74643 Deuruxolitinib improves scalp hair regrowth over time in patients with severe alopecia areata: Pooled analysis of the THRIVE-AA1 and THRIVE-AA2 Phase 3 trials